NASDAQ: CNXUConexeu Sciences Inc Stock
$13.77-0.63 (-4.38%)
Updated May 26, 2026
CNXU Price
$13.77
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$12.31
52 Week High
$17.50
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
N/A
Beta
-61.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNXU Overview
Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company was founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell on November 2, 2022 and is headquartered in Reno, NV.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNXU's potential to beat the market
- CNXU doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNXU
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.41 | A | |
| $49.98 | A | |
| $15.19 | A |
Be the first to know about important CNXU news, forecast changes, insider trades & much more!
CNXU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNXU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNXU's short-term assets ($7.46M) exceed its short-term liabilities ($876.28k)
Short-term Liabilities Financials
CNXU's short-term assets ($7.46M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
CNXU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
There are 30 more CNXU due diligence checks available for Premium users.
Valuation
CNXU's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.7M
Profit Margin
0%
Assets to liabilities
Assets
$7.7M
Liabilities
$876.3k
Debt to equity
0.13
CNXU's short-term assets ($7.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNXU's short-term assets ($7.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNXU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
-$4.7k
Financing
$3.4M
Conexeu Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.